Industry Research Reports

Home > Reports > Chemical & Material > Global Lenalidomide API Market Outlook, In‑Depth Analysis & Forecast to 2031

Global Lenalidomide API Market Outlook, In‑Depth Analysis & Forecast to 2031

Industry: Chemical & Material

Published Date: 2025-10-22

Pages: 139 Pages

Report ld: 5200520

Request Sample

Customized Report

Description
Table of Contents
Table of Figures
Related Reports
PDF Download

Description
Table of Contents
Table of Figures
Related Reports
PDF Download

The global Lenalidomide API market is projected to grow from US$ million in 2024 to US$ million by 2031, at a CAGR of %(2025-2031), driven by critical product segments and diverse end‑use applications, while evolving U.S. tariff policies introduce trade‑cost volatility and supply‑chain uncertainty.

Thalidomide and its analogue lenalidomide are immunomodulatory and antineoplastic agents that are used in the therapy of multiple myeloma. Both agents are associated with a low rate of serum aminotransferase elevations during therapy and both have been implicated in causing rare instances of clinically apparent liver injury which can be severe.

From a downstream perspective, Lenalidomide capsules accounted for % of 2024 revenue, surging to US$ million by 2031 (CAGR: % from 2025–2031).

Lenalidomide API leading manufacturers including Dr. Reddy’s Laboratories Ltd., Johnson Matthey PLC, Changzhou Pharmaceutical Factory, Shilpa Medicare Limited, Biocon Limited, Sun Pharmaceutical Industries Ltd., Shenzhen Haorui, Mac-Chem Products (India) Pvt.Ltd, etc., dominate supply; the top five capture approximately % of global revenue, with Dr. Reddy’s Laboratories Ltd. leading 2024 sales at US$ million.

Regional Outlook:

North America rose from US$ million in 2024 to a forecast US$ million by 2031 (CAGR %).

Asia‑Pacific will expand from US$ million to US$ million (CAGR  %), led by China (US$ million in 2024, % share rising to % by 2031), Japan (CAGR %), South Korea (CAGR %), and Southeast Asia (CAGR %).

Europe is set to grow from US$ million to US$ million (CAGR %), with Germany projected to hit US$ million by 2031 (CAGR %).

Report Includes:

This definitive report equips business leaders, decision-makers and stakeholders with a 360° view of the global Lenalidomide API market, seamlessly integrating production capacity and sales performance across the value chain. It analyzes historical production, revenue, and sales data (2020–2024) and delivers forecasts through 2031, illuminating demand trends and growth drivers.

By segmenting the market by Type and by Application, the study quantifies volume and value, growth rates, technical innovations, niche opportunities, and substitution risks, and analyzes downstream customers distribution pattern.

Granular regional insights cover five major markets—North America, Europe, APAC, South America, and MEA—with in‑depth analysis of 20+ countries. Each region’s dominant products, competitive landscape, and downstream demand trends are clearly detailed.

Critical competitive intelligence profiles manufacturers—capacity, sales volume, revenue, margins, pricing strategies, and major customers—and dissects the top-player positioning across product lines, applications, and regions to reveal strategic strengths.

A concise supply‑chain overview maps upstream suppliers, manufacturing technologies, cost structures, and distribution dynamics to identify strategic gaps and unmet demand.

MARKET SEGMENTATION

By Company

Dr. Reddy’s Laboratories Ltd.
Johnson Matthey PLC
Changzhou Pharmaceutical Factory
Shilpa Medicare Limited
Biocon Limited
Sun Pharmaceutical Industries Ltd.
Shenzhen Haorui
Mac-Chem Products (India) Pvt.Ltd

Consumption by Region

North America
- United States
- Canada
Asia-Pacific
- China
- Japan
- South Korea
- Southeast Asia
- India
- Australia
- Rest of Asia-Pacific
Europe
- Germany
- France
- U.K.
- Italy
- Netherlands
- Nordic Countries
- Rest of Europe
Latin America
- Mexico
- Brazil
- Rest of Latin America
Middle East & Africa
- Turkey
- Saudi Arabia
- UAE
- Rest of MEA

Segment by Type

Purity≥98%
Purity<98%

Segment by Application

Lenalidomide capsules
Others

biaoTi CHAPTER OUTLINE

Chapter 1: Defines the Lenalidomide API study scope, segments the market by Type and by Application, etc, highlights segment size and growth potential.

Chapter 2: Offers current market state, projects global revenue and sales to 2031, pinpointing high consumption regions and emerging market catalysts

Chapter 3: Maps global production capacity, utilization, and market share (2020–2031), identifies efficient hubs, reveals regulatory/trade policy impacts and bottlenecks.

Chapter 4: Dissects the manufacturer landscape—ranks by volume and revenue, analyzes profitability and pricing, maps production bases, details manufacturer performance by product type and evaluates concentration alongside M&A moves.

Chapter 5: Unlocks high margin product segments—compares sales, revenue, ASP, and technology differentiators, highlighting growth niches and substitution risks

Chapter 6: Targets downstream market opportunities—evaluates sales, revenue, and pricing by Application, identifies emerging use cases, and profiles leading customers by region and by Application.

Chapter 7: North America—breaks down sales and revenue by Type, by Application and country, profiles key manufacturers and assesses growth drivers and barriers.

Chapter 8: Europe—analyses regional sales, revenue and market by Type, by Application and manufacturers, flagging drivers and barriers.

Chapter 9: Asia Pacific—quantifies sales and revenue by Type, by Application, and region/country, profiles top manufacturers, and uncovers high potential expansion areas.

Chapter 10: Central & South America—measures sales and revenue by Type, by Application, and country, profiles top manufacturers, and identifies investment opportunities and challenges.

Chapter 11: Middle East and Africa—evaluates sales and revenue by Type, by Application, and country, profiles key manufacturers, and outlines investment prospects and market hurdles

Chapter 12: Profiles manufacturers in depth—details product specs, capacity, sales, revenue, margins; top manufactures 2024 sales breakdowns by product type, by Application, by sales region SWOT analysis, and recent strategic developments.

Chapter 13: Supply chain—analyses upstream raw materials and suppliers, manufacturing footprint and technology, cost drivers, plus downstream channels and distributor roles.

Chapter 14: Market dynamics—explores drivers, restraints, regulatory impacts, and risk mitigation strategies.

Chapter 15: Actionable conclusions and strategic recommendations.

WHY THIS REPORT

Beyond standard market data, this analysis provides a clear profitability roadmap, empowering you to:

Beyond standard market data, this analysis provides a clear profitability roadmap—empowering you to:

Allocate capital strategically to high growth regions (Chapters 7–11) and margin rich segments (Chapter 5).

Negotiate from strength with suppliers (Chapter 13) and customers (Chapter 6) using cost and demand intelligence.

Outmaneuver competitors with granular insights into their operations, margins, and strategies (Chapters 4 and 12).

Secure your supply chain against disruptions through upstream and downstream visibility (Chapters 13 and 14).

Leverage this 360° intelligence to turn market complexity into actionable competitive advantage.

biaoTi QYRESEARCH'S STRENGTHS

Unlike generic global market reports, this study combines macro-level industry trends with hyper-local operational intelligence, empowering data-driven decisions across the Compound Chocolate value chain, addressing:

Market entry risks/opportunities by region

We identify regional market threats and growth prospects to guide your overseas layout.

Product mix optimization based on local practices

We adjust product portfolios in line with local consumption habits.

Competitor tactics in fragmented vs. consolidated markets

We unpack rivals’ operation strategies for scattered and highly concentrated industries.

Full Research Coverage

We cover competition landscape, full supply chain and quantified market size data, and deliver tailor-made customized surveys to meet your unique business demands.

19 Years Industry Expertise

We own self-owned massive exclusive databases, backed by 19 years of global market research experience across thousands of sectors.

24/7 Fast Report Delivery

Our team operates 24 hours a day, 365 days a year, enabling ultra-fast report turnaround to respond to your research needs efficiently.

Localized Strategic Analysis

We integrate regional risk assessment, localized product optimization and competitor analysis to deliver actionable market strategies.

Market entry risks/opportunities by region

All data is cross-verified from multiple industry sources to deliver thorough, precise analysis that supports reliable corporate strategic decisions.

Market entry risks/opportunities by region

We provide responsive, dedicated after-sales support to resolve all follow-up inquiries about reports, data and industry interpretation.

TABLE OF CONTENTS

1 Study Coverage

1.1 Introduction to Lenalidomide API: Definition, Properties, and Key Attributes

1.2 Market Segmentation by Type

1.2.1 Global Lenalidomide API Market Size by Type, 2020 VS 2024 VS 2031

1.2.2 Purity≥98%

1.2.3 Purity<98%

1.3 Market Segmentation by Application

1.3.1 Global Lenalidomide API Market Size by Application, 2020 VS 2024 VS 2031

1.3.2 Lenalidomide capsules

1.3.3 Others

1.4 Assumptions and Limitations

1.5 Study Objectives

1.6 Years Considered

2 Executive Summary

2.1 Global Lenalidomide API Revenue Estimates and Forecasts 2020-2031

2.2 Global Lenalidomide API Revenue by Region

2.2.1 Revenue Comparison: 2020 VS 2024 VS 2031

2.2.2 Historical and Forecasted Revenue by Region (2020--2031)

2.2.3 Global Revenue Market Share by Region (2020-2031)

2.3 Global Lenalidomide API Sales Estimates and Forecasts 2020-2031

2.4 Global Lenalidomide API Sales by Region

2.4.1 Sales Comparison: 2020 VS 2024 VS 2031

2.4.2 Historical and Forecasted Sales by Region (2020-2031)

2.4.3 Emerging Market Focus: Growth Drivers & Investment Trends

2.4.4 Global Sales Market Share by Region (2020-2031)

3 Global Production Analysis

3.1 Global Lenalidomide API Production Capacity and Utilization Rates (2020–2031)

3.2 Regional Production: Comparative Analysis (2020 VS 2024 VS 2031)

3.3 Regional Production Dynamics

3.3.1 Historic Production by Region (2020-2025)

3.3.2 Forecasted Production by Region (2026-2031)

3.3.3 Production Market Share by Region (2020-2031)

3.3.4 Regulatory and Trade Policy Impact on Production

3.3.5 Production Capacity Enablers and Constraints

3.4 Key Regional Production Hubs

3.4.1 India

3.4.2 Europe

3.4.3 China

4 Competition by Manufacturers

4.1 Global Lenalidomide API Sales by Manufacturers

4.1.1 Global Sales Volume by Manufacturers (2020-2025)

4.1.2 Global Top 5 and Top 10 Manufacturers’Market Share by Sales Volume (2024)

4.2 Global Lenalidomide API Manufacturer Revenue Rankings and Tiers

4.2.1 Global Revenue (Value) by Manufacturers (2020-2025)

4.2.2 Global Key Manufacturer Revenue Ranking (2023 vs. 2024)

4.2.3 Revenue-Based Tier Segmentation (Tier 1, Tier 2, and Tier 3)

4.3 Manufacturer Profitability Profiles and Pricing Strategies

4.3.1 Gross Margin by Top Manufacturer (2020 VS 2024)

4.3.2 Manufacturer-Level Price Trends (2020-2025)

4.4 Key Manufacturers Manufacturing Base and Headquarters

4.5 Main Product Type Market Size by Manufacturers

4.5.1 Purity≥98% Market Size by Manufacturers

4.5.2 Purity<98% Market Size by Manufacturers

4.6 Global Lenalidomide API Market Concentration and Dynamics

4.6.1 Global Market Concentration (CR5 and HHI)

4.6.2 Entrant/Exit Impact Analysis

4.6.3 Strategic Moves: M&A, Capacity Expansion, R&D Investment

5 Global Product Segmentation Analysis

5.1 Global Lenalidomide API Sales Performance by Type

5.1.1 Global Historical and Forecasted Sales by Type (2020-2031)

5.1.2 Global Sales Market Share by Type (2020-2031)

5.2 Global Lenalidomide API Revenue Trends by Type

5.2.1 Global Historical and Forecasted Revenue by Type (2020-2031)

5.2.2 Global Revenue Market Share by Type (2020-2031)

5.3 Global Average Selling Price (ASP) Trends by Type (2020-2031)

5.4 Product Technology Differentiation

5.5 Subtype Dynamics: Growth Leaders, Profitability and Risk

5.5.1 High-Growth Niches and Adoption Drivers

5.5.2 Profitability Hotspots and Cost Drivers

5.5.3 Substitution Threats

6 Global Downstream Application Analysis

6.1 Global Lenalidomide API Sales by Application

6.1.1 Global Historical and Forecasted Sales by Application (2020-2031)

6.1.2 Global Sales Market Share by Application (2020-2031)

6.1.3 High-Growth Application Identification

6.1.4 Emerging Application Case Studies

6.2 Global Lenalidomide API Revenue by Application

6.2.1 Global Historical and Forecasted Revenue by Application (2020-2031)

6.2.2 Revenue Market Share by Application (2020-2031)

6.3 Global Pricing Dynamics by Application (2020-2031)

6.4 Downstream Customer Analysis

6.4.1 Top Customers by Region

6.4.2 Top Customers by Application

7 North America

7.1 North America Sales Volume and Revenue (2020-2031)

7.2 North America Key Manufacturers Sales Revenue in 2024

7.3 North America Lenalidomide API Sales and Revenue by Type (2020-2031)

7.4 North America Lenalidomide API Sales and Revenue by Application (2020-2031)

7.5 North America Growth Accelerators and Market Barriers

7.6 North America Lenalidomide API Market Size by Country

7.6.1 North America Revenue by Country

7.6.2 North America Sales Trends by Country

7.6.3 US

7.6.4 Canada

7.6.5 Mexico

8 Europe

8.1 Europe Sales Volume and Revenue (2020-2031)

8.2 Europe Key Manufacturers Sales Revenue in 2024

8.3 Europe Lenalidomide API Sales and Revenue by Type (2020-2031)

8.4 Europe Lenalidomide API Sales and Revenue by Application (2020-2031)

8.5 Europe Growth Accelerators and Market Barriers

8.6 Europe Lenalidomide API Market Size by Country

8.6.1 Europe Revenue by Country

8.6.2 Europe Sales Trends by Country

8.6.3 Germany

8.6.4 France

8.6.5 U.K.

8.6.6 Italy

8.6.7 Russia

9 Asia-Pacific

9.1 Asia-Pacific Sales Volume and Revenue (2020-2031)

9.2 Asia-Pacific Key Manufacturers Sales Revenue in 2024

9.3 Asia-Pacific Lenalidomide API Sales and Revenue by Type (2020-2031)

9.4 Asia-Pacific Lenalidomide API Sales and Revenue by Application (2020-2031)

9.5 Asia-Pacific Lenalidomide API Market Size by Region

9.5.1 Asia-Pacific Revenue by Region

9.5.2 Asia-Pacific Sales Trends by Region

9.6 Asia-Pacific Growth Accelerators and Market Barriers

9.7 Southeast Asia

9.7.1 Southeast Asia Revenue by Country (2020 VS 2024 VS 2031)

9.7.2 Key Country Analysis: Indonesia, Vietnam, Thailand

9.8 China

9.9 Japan

9.10 South Korea

9.11 China Taiwan

9.12 India

10 Central and South America

10.1 Central and South America Sales Volume and Revenue (2020-2031)

10.2 Central and South America Key Manufacturers Sales Revenue in 2024

10.3 Central and South America Lenalidomide API Sales and Revenue by Type (2020-2031)

10.4 Central and South America Lenalidomide API Sales and Revenue by Application (2020-2031)

10.5 Central and South America Investment Opportunities and Key Challenges

10.6 Central and South America Lenalidomide API Market Size by Country

10.6.1 Central and South America Revenue Trends by Country (2020 VS 2024 VS 2031)

10.6.2 Brazil

10.6.3 Argentina

11 Middle East and Africa

11.1 Middle East and Africa Sales Volume and Revenue (2020-2031)

11.2 Middle East and Africa Key Manufacturers Sales Revenue in 2024

11.3 Middle East and Africa Lenalidomide API Sales and Revenue by Type (2020-2031)

11.4 Middle East and Africa Lenalidomide API Sales and Revenue by Application (2020-2031)

11.5 Middle East and Africa Investment Opportunities and Key Challenges

11.6 Middle East and Africa Lenalidomide API Market Size by Country

11.6.1 Middle East and Africa Revenue Trends by Country (2020 VS 2024 VS 2031)

11.6.2 GCC Countries

11.6.3 Turkey

11.6.4 Egypt

11.6.5 South Africa

12 Corporate Profile

12.1 Dr. Reddy’s Laboratories Ltd.

12.1.1 Dr. Reddy’s Laboratories Ltd. Corporation Information

12.1.2 Dr. Reddy’s Laboratories Ltd. Business Overview

12.1.3 Dr. Reddy’s Laboratories Ltd. Lenalidomide API Product Models, Descriptions and Specifications

12.1.4 Dr. Reddy’s Laboratories Ltd. Lenalidomide API Capacity, Sales, Price, Revenue and Gross Margin (2020-2025)

12.1.5 Dr. Reddy’s Laboratories Ltd. Lenalidomide API Sales by Product in 2024

12.1.6 Dr. Reddy’s Laboratories Ltd. Lenalidomide API Sales by Application in 2024

12.1.7 Dr. Reddy’s Laboratories Ltd. Lenalidomide API Sales by Geographic Area in 2024

12.1.8 Dr. Reddy’s Laboratories Ltd. Lenalidomide API SWOT Analysis

12.1.9 Dr. Reddy’s Laboratories Ltd. Recent Developments

12.2 Johnson Matthey PLC

12.2.1 Johnson Matthey PLC Corporation Information

12.2.2 Johnson Matthey PLC Business Overview

12.2.3 Johnson Matthey PLC Lenalidomide API Product Models, Descriptions and Specifications

12.2.4 Johnson Matthey PLC Lenalidomide API Capacity, Sales, Price, Revenue and Gross Margin (2020-2025)

12.2.5 Johnson Matthey PLC Lenalidomide API Sales by Product in 2024

12.2.6 Johnson Matthey PLC Lenalidomide API Sales by Application in 2024

12.2.7 Johnson Matthey PLC Lenalidomide API Sales by Geographic Area in 2024

12.2.8 Johnson Matthey PLC Lenalidomide API SWOT Analysis

12.2.9 Johnson Matthey PLC Recent Developments

12.3 Changzhou Pharmaceutical Factory

12.3.1 Changzhou Pharmaceutical Factory Corporation Information

12.3.2 Changzhou Pharmaceutical Factory Business Overview

12.3.3 Changzhou Pharmaceutical Factory Lenalidomide API Product Models, Descriptions and Specifications

12.3.4 Changzhou Pharmaceutical Factory Lenalidomide API Capacity, Sales, Price, Revenue and Gross Margin (2020-2025)

12.3.5 Changzhou Pharmaceutical Factory Lenalidomide API Sales by Product in 2024

12.3.6 Changzhou Pharmaceutical Factory Lenalidomide API Sales by Application in 2024

12.3.7 Changzhou Pharmaceutical Factory Lenalidomide API Sales by Geographic Area in 2024

12.3.8 Changzhou Pharmaceutical Factory Lenalidomide API SWOT Analysis

12.3.9 Changzhou Pharmaceutical Factory Recent Developments

12.4 Shilpa Medicare Limited

12.4.1 Shilpa Medicare Limited Corporation Information

12.4.2 Shilpa Medicare Limited Business Overview

12.4.3 Shilpa Medicare Limited Lenalidomide API Product Models, Descriptions and Specifications

12.4.4 Shilpa Medicare Limited Lenalidomide API Capacity, Sales, Price, Revenue and Gross Margin (2020-2025)

12.4.5 Shilpa Medicare Limited Lenalidomide API Sales by Product in 2024

12.4.6 Shilpa Medicare Limited Lenalidomide API Sales by Application in 2024

12.4.7 Shilpa Medicare Limited Lenalidomide API Sales by Geographic Area in 2024

12.4.8 Shilpa Medicare Limited Lenalidomide API SWOT Analysis

12.4.9 Shilpa Medicare Limited Recent Developments

12.5 Biocon Limited

12.5.1 Biocon Limited Corporation Information

12.5.2 Biocon Limited Business Overview

12.5.3 Biocon Limited Lenalidomide API Product Models, Descriptions and Specifications

12.5.4 Biocon Limited Lenalidomide API Capacity, Sales, Price, Revenue and Gross Margin (2020-2025)

12.5.5 Biocon Limited Lenalidomide API Sales by Product in 2024

12.5.6 Biocon Limited Lenalidomide API Sales by Application in 2024

12.5.7 Biocon Limited Lenalidomide API Sales by Geographic Area in 2024

12.5.8 Biocon Limited Lenalidomide API SWOT Analysis

12.5.9 Biocon Limited Recent Developments

12.6 Sun Pharmaceutical Industries Ltd.

12.6.1 Sun Pharmaceutical Industries Ltd. Corporation Information

12.6.2 Sun Pharmaceutical Industries Ltd. Business Overview

12.6.3 Sun Pharmaceutical Industries Ltd. Lenalidomide API Product Models, Descriptions and Specifications

12.6.4 Sun Pharmaceutical Industries Ltd. Lenalidomide API Capacity, Sales, Price, Revenue and Gross Margin (2020-2025)

12.6.5 Sun Pharmaceutical Industries Ltd. Recent Developments

12.7 Shenzhen Haorui

12.7.1 Shenzhen Haorui Corporation Information

12.7.2 Shenzhen Haorui Business Overview

12.7.3 Shenzhen Haorui Lenalidomide API Product Models, Descriptions and Specifications

12.7.4 Shenzhen Haorui Lenalidomide API Capacity, Sales, Price, Revenue and Gross Margin (2020-2025)

12.7.5 Shenzhen Haorui Recent Developments

12.8 Mac-Chem Products (India) Pvt.Ltd

12.8.1 Mac-Chem Products (India) Pvt.Ltd Corporation Information

12.8.2 Mac-Chem Products (India) Pvt.Ltd Business Overview

12.8.3 Mac-Chem Products (India) Pvt.Ltd Lenalidomide API Product Models, Descriptions and Specifications

12.8.4 Mac-Chem Products (India) Pvt.Ltd Lenalidomide API Capacity, Sales, Price, Revenue and Gross Margin (2020-2025)

12.8.5 Mac-Chem Products (India) Pvt.Ltd Recent Developments

13 Value Chain and Supply-Chain Analysis

13.1 Lenalidomide API Industry Chain

13.2 Lenalidomide API Upstream Materials Analysis

13.2.1 Raw Materials

13.2.2 Key Suppliers Market Share & Risk Assessment

13.3 Lenalidomide API Integrated Production Analysis

13.3.1 Manufacturing Footprint Analysis

13.3.2 Production Technology Overview

13.3.3 Regional Cost Drivers

13.4 Lenalidomide API Sales Channels and Distribution Networks

13.4.1 Sales Channels

13.4.2 Distributors

14 Lenalidomide API Market Dynamics

14.1 Industry Trends and Evolution

14.2 Market Growth Drivers and Emerging Opportunities

14.3 Market Challenges, Risks, and Restraints

15 Key Findings in the Global Lenalidomide API Study

16 Appendix

16.1 Research Methodology

16.1.1 Methodology/Research Approach

16.1.1.1 Research Programs/Design

16.1.1.2 Market Size Estimation

16.1.1.3 Market Breakdown and Data Triangulation

16.1.2 Data Source

16.1.2.1 Secondary Sources

16.1.2.2 Primary Sources

16.2 Author Details

TABLE OF FIGURES

List of Tables

Table 1. Global Lenalidomide API Market Size Growth Rate by Type, 2020 VS 2024 VS 2031 (US$ Million)

Table 2. Global Lenalidomide API Market Size Growth Rate by Application, 2020 VS 2024 VS 2031 (US$ Million)

Table 3. Global Lenalidomide API Revenue Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)

Table 4. Global Lenalidomide API Revenue by Region (2020-2025) & (US$ Million)

Table 5. Global Lenalidomide API Revenue by Region (2026-2031) & (US$ Million)

Table 6. Global Lenalidomide API Sales Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (Ton)

Table 7. Global Lenalidomide API Sales by Region (2020-2025) & (Ton)

Table 8. Global Lenalidomide API Sales by Region (2026-2031) & (Ton)

Table 9. Emerging Market Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)

Table 10. Global Lenalidomide API Production Growth Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (Ton)

Table 11. Global Lenalidomide API Production by Region (2020-2025) & (Ton)

Table 12. Global Lenalidomide API Production by Region (2026-2031) & (Ton)

Table 13. Global Lenalidomide API Sales by Manufacturers (2020-2025) & (Ton)

Table 14. Global Lenalidomide API Sales Share by Manufacturers (2020-2025)

Table 15. Global Lenalidomide API Revenue by Manufacturers (2020-2025) & (US$ Million)

Table 16. Global Lenalidomide API Revenue Market Share by Manufacturers (2020-2025)

Table 17. Global Key Manufacturers’Ranking Shift (2023 vs. 2024) (Based on Revenue)

Table 18. Global Lenalidomide API by Manufacturer Tier (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Lenalidomide API as of 2024)

Table 19. Global Lenalidomide API Average Gross Margin (%) by Manufacturer (2020 VS 2024)

Table 20. Global Lenalidomide API Average Selling Price (ASP) by Manufacturers (2020-2025) & (US$/Ton)

Table 21. Key Manufacturers Lenalidomide API Manufacturing Base and Headquarters

Table 22. Global Lenalidomide API Market Concentration Ratio (CR5 and HHI)

Table 23. Key Market Entrant/Exit (2020-2024) – Drivers & Impact Analysis

Table 24. Key Mergers & Acquisitions, Expansion Plans, R&D Investment

Table 25. Global Lenalidomide API Sales by Type (2020-2025) & (Ton)

Table 26. Global Lenalidomide API Sales by Type (2026-2031) & (Ton)

Table 27. Global Lenalidomide API Revenue by Type (2020-2025) & (US$ Million)

Table 28. Global Lenalidomide API Revenue by Type (2026-2031) & (US$ Million)

Table 29. Global Lenalidomide API ASP by Type (2020-2031) & (US$/Ton)

Table 30. Technical Specifications by Key Product Type

Table 31. Global Lenalidomide API Sales by Application (2020-2025) & (Ton)

Table 32. Global Lenalidomide API Sales by Application (2026-2031) & (Ton)

Table 33. Lenalidomide API High-Growth Sectors Demand CAGR (2024-2031)

Table 34. Global Lenalidomide API Revenue by Application (2020-2025) & (US$ Million)

Table 35. Global Lenalidomide API Revenue by Application (2026-2031) & (US$ Million)

Table 36. Global Lenalidomide API ASP by Application (2020-2031) & (US$/Ton)

Table 37. Top Customers by Region

Table 38. Top Customers by Application

Table 39. North America Lenalidomide API Growth Accelerators and Market Barriers

Table 40. North America Lenalidomide API Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)

Table 41. North America Lenalidomide API Sales (Ton) by Country (2020 VS 2024 VS 2031)

Table 42. Europe Lenalidomide API Growth Accelerators and Market Barriers

Table 43. Europe Lenalidomide API Revenue Grow Rate (CAGR) by Country: 2020 VS 2024 VS 2031 (US$ Million)

Table 44. Europe Lenalidomide API Sales (Ton) by Country (2020 VS 2024 VS 2031)

Table 45. Asia-Pacific Lenalidomide API Revenue Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)

Table 46. Asia-Pacific Lenalidomide API Sales (Ton) by Country (2020 VS 2024 VS 2031)

Table 47. Asia-Pacific Lenalidomide API Growth Accelerators and Market Barriers

Table 48. Southeast Asia Lenalidomide API Revenue Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)

Table 49. Central and South America Lenalidomide API Investment Opportunities and Key Challenges

Table 50. Central and South America Lenalidomide API Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)

Table 51. Middle East and Africa Lenalidomide API Investment Opportunities and Key Challenges

Table 52. Middle East and Africa Lenalidomide API Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)

Table 53. Dr. Reddy’s Laboratories Ltd. Corporation Information

Table 54. Dr. Reddy’s Laboratories Ltd. Description and Major Businesses

Table 55. Dr. Reddy’s Laboratories Ltd. Product Models, Descriptions and Specifications

Table 56. Dr. Reddy’s Laboratories Ltd. Capacity, Sales (Ton), Revenue (US$ Million), Price (US$/Ton) and Gross Margin (2020-2025)

Table 57. Dr. Reddy’s Laboratories Ltd. Sales Value Proportion by Product in 2024

Table 58. Dr. Reddy’s Laboratories Ltd. Sales Value Proportion by Application in 2024

Table 59. Dr. Reddy’s Laboratories Ltd. Sales Value Proportion by Geographic Area in 2024

Table 60. Dr. Reddy’s Laboratories Ltd. Lenalidomide API SWOT Analysis

Table 61. Dr. Reddy’s Laboratories Ltd. Recent Developments

Table 62. Johnson Matthey PLC Corporation Information

Table 63. Johnson Matthey PLC Description and Major Businesses

Table 64. Johnson Matthey PLC Product Models, Descriptions and Specifications

Table 65. Johnson Matthey PLC Capacity, Sales (Ton), Revenue (US$ Million), Price (US$/Ton) and Gross Margin (2020-2025)

Table 66. Johnson Matthey PLC Sales Value Proportion by Product in 2024

Table 67. Johnson Matthey PLC Sales Value Proportion by Application in 2024

Table 68. Johnson Matthey PLC Sales Value Proportion by Geographic Area in 2024

Table 69. Johnson Matthey PLC Lenalidomide API SWOT Analysis

Table 70. Johnson Matthey PLC Recent Developments

Table 71. Changzhou Pharmaceutical Factory Corporation Information

Table 72. Changzhou Pharmaceutical Factory Description and Major Businesses

Table 73. Changzhou Pharmaceutical Factory Product Models, Descriptions and Specifications

Table 74. Changzhou Pharmaceutical Factory Capacity, Sales (Ton), Revenue (US$ Million), Price (US$/Ton) and Gross Margin (2020-2025)

Table 75. Changzhou Pharmaceutical Factory Sales Value Proportion by Product in 2024

Table 76. Changzhou Pharmaceutical Factory Sales Value Proportion by Application in 2024

Table 77. Changzhou Pharmaceutical Factory Sales Value Proportion by Geographic Area in 2024

Table 78. Changzhou Pharmaceutical Factory Lenalidomide API SWOT Analysis

Table 79. Changzhou Pharmaceutical Factory Recent Developments

Table 80. Shilpa Medicare Limited Corporation Information

Table 81. Shilpa Medicare Limited Description and Major Businesses

Table 82. Shilpa Medicare Limited Product Models, Descriptions and Specifications

Table 83. Shilpa Medicare Limited Capacity, Sales (Ton), Revenue (US$ Million), Price (US$/Ton) and Gross Margin (2020-2025)

Table 84. Shilpa Medicare Limited Sales Value Proportion by Product in 2024

Table 85. Shilpa Medicare Limited Sales Value Proportion by Application in 2024

Table 86. Shilpa Medicare Limited Sales Value Proportion by Geographic Area in 2024

Table 87. Shilpa Medicare Limited Lenalidomide API SWOT Analysis

Table 88. Shilpa Medicare Limited Recent Developments

Table 89. Biocon Limited Corporation Information

Table 90. Biocon Limited Description and Major Businesses

Table 91. Biocon Limited Product Models, Descriptions and Specifications

Table 92. Biocon Limited Capacity, Sales (Ton), Revenue (US$ Million), Price (US$/Ton) and Gross Margin (2020-2025)

Table 93. Biocon Limited Sales Value Proportion by Product in 2024

Table 94. Biocon Limited Sales Value Proportion by Application in 2024

Table 95. Biocon Limited Sales Value Proportion by Geographic Area in 2024

Table 96. Biocon Limited Lenalidomide API SWOT Analysis

Table 97. Biocon Limited Recent Developments

Table 98. Sun Pharmaceutical Industries Ltd. Corporation Information

Table 99. Sun Pharmaceutical Industries Ltd. Description and Major Businesses

Table 100. Sun Pharmaceutical Industries Ltd. Product Models, Descriptions and Specifications

Table 101. Sun Pharmaceutical Industries Ltd. Capacity, Sales (Ton), Revenue (US$ Million), Price (US$/Ton) and Gross Margin (2020-2025)

Table 102. Sun Pharmaceutical Industries Ltd. Recent Developments

Table 103. Shenzhen Haorui Corporation Information

Table 104. Shenzhen Haorui Description and Major Businesses

Table 105. Shenzhen Haorui Product Models, Descriptions and Specifications

Table 106. Shenzhen Haorui Capacity, Sales (Ton), Revenue (US$ Million), Price (US$/Ton) and Gross Margin (2020-2025)

Table 107. Shenzhen Haorui Recent Developments

Table 108. Mac-Chem Products (India) Pvt.Ltd Corporation Information

Table 109. Mac-Chem Products (India) Pvt.Ltd Description and Major Businesses

Table 110. Mac-Chem Products (India) Pvt.Ltd Product Models, Descriptions and Specifications

Table 111. Mac-Chem Products (India) Pvt.Ltd Capacity, Sales (Ton), Revenue (US$ Million), Price (US$/Ton) and Gross Margin (2020-2025)

Table 112. Mac-Chem Products (India) Pvt.Ltd Recent Developments

Table 113. Key Raw Materials Distribution

Table 114. Raw Materials Key Suppliers

Table 115. Critical Raw Material Supplier Concentration (2024) & Risk Index

Table 116. Milestones in Production Technology Evolution

Table 117. Distributors List

Table 118. Market Trends and Market Evolution

Table 119. Market Drivers and Opportunities

Table 120. Market Challenges, Risks, and Restraints

Table 121. Research Programs/Design for This Report

Table 122. Key Data Information from Secondary Sources

Table 123. Key Data Information from Primary Sources

List of Figures

Figure 1. Lenalidomide API Product Picture

Figure 2. Global Lenalidomide API Market Size Growth Rate by Type, 2020 VS 2024 VS 2031 (US$ Million)

Figure 3. Purity≥98% Product Picture

Figure 4. Purity<98% Product Picture

Figure 5. Global Lenalidomide API Market Size Growth Rate by Application, 2020 VS 2024 VS 2031 (US$ Million)

Figure 6. Lenalidomide capsules

Figure 7. Others

Figure 8. Lenalidomide API Report Years Considered

Figure 9. Global Lenalidomide API Revenue, (US$ Million), 2020 VS 2024 VS 2031

Figure 10. Global Lenalidomide API Revenue (2020-2031) & (US$ Million)

Figure 11. Global Lenalidomide API Revenue (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)

Figure 12. Global Lenalidomide API Revenue Market Share by Region (2020-2031)

Figure 13. Global Lenalidomide API Sales (2020-2031) & (Ton)

Figure 14. Global Lenalidomide API Sales (CAGR) by Region (2020-2031) (Ton)

Figure 15. Global Lenalidomide API Sales Market Share by Region (2020-2031)

Figure 16. Global Lenalidomide API Capacity, Production and Utilization (2020-2031) & (Ton)

Figure 17. Global Lenalidomide API Production Trend by Region (2020-2031) (Ton)

Figure 18. Global Lenalidomide API Production Market Share by Region (2020-2031)

Figure 19. Production Capacity Enablers & Constraints

Figure 20. Lenalidomide API Production Growth Rate in India (2020-2031) & (Ton)

Figure 21. Lenalidomide API Production Growth Rate in Europe (2020-2031) & (Ton)

Figure 22. Lenalidomide API Production Growth Rate in China (2020-2031) & (Ton)

Figure 23. Top 5 and Top 10 Manufacturers Lenalidomide API Sales Volume Market Share in 2024

Figure 24. Global Lenalidomide API Revenue Market Share Ranking (2024)

Figure 25. Tier Distribution by Revenue Contribution (2020 VS 2024)

Figure 26. Purity≥98% Revenue Market Share by Manufacturer in 2024

Figure 27. Purity<98% Revenue Market Share by Manufacturer in 2024

Figure 28. Type Eight Revenue Market Share by Manufacturer in 2024

Figure 29. Type Nine Revenue Market Share by Manufacturer in 2024

Figure 30. Global Lenalidomide API Sales Market Share by Type (2020-2031)

Figure 31. Global Lenalidomide API Revenue Market Share by Type (2020-2031)

Figure 32. Global Lenalidomide API Sales Market Share by Application (2020-2031)

Figure 33. Global Lenalidomide API Revenue Market Share by Application (2020-2031)

Figure 34. North America Lenalidomide API Sales YoY (2020-2031) & (Ton)

Figure 35. North America Lenalidomide API Revenue YoY (2020-2031) & (US$ Million)

Figure 36. North America Top 5 Manufacturers Lenalidomide API Sales Revenue (US$ Million) in 2024

Figure 37. North America Lenalidomide API Sales Volume (Ton) by Type (2020- 2031)

Figure 38. North America Lenalidomide API Sales Revenue (US$ Million) by Type (2020 - 2031)

Figure 39. North America Lenalidomide API Sales Volume (Ton) by Application (2020-2031)

Figure 40. North America Lenalidomide API Sales Revenue (US$ Million) by Application (2020-2031)

Figure 41. US Lenalidomide API Revenue (2020-2031) & (US$ Million)

Figure 42. Canada Lenalidomide API Revenue (2020-2031) & (US$ Million)

Figure 43. Mexico Lenalidomide API Revenue (2020-2031) & (US$ Million)

Figure 44. Europe Lenalidomide API Sales YoY (2020-2031) & (Ton)

Figure 45. Europe Lenalidomide API Revenue YoY (2020-2031) & (US$ Million)

Figure 46. Europe Top 5 Manufacturers Lenalidomide API Sales Revenue (US$ Million) in 2024

Figure 47. Europe Lenalidomide API Sales Volume (Ton) by Type (2020-2031)

Figure 48. Europe Lenalidomide API Sales Revenue (US$ Million) by Type (2020-2031)

Figure 49. Europe Lenalidomide API Sales Volume (Ton) by Application (2020-2031)

Figure 50. Europe Lenalidomide API Sales Revenue (US$ Million) by Application (2020-2031)

Figure 51. Germany Lenalidomide API Revenue (2020-2031) & (US$ Million)

Figure 52. France Lenalidomide API Revenue (2020-2031) & (US$ Million)

Figure 53. U.K. Lenalidomide API Revenue (2020-2031) & (US$ Million)

Figure 54. Italy Lenalidomide API Revenue (2020-2031) & (US$ Million)

Figure 55. Russia Lenalidomide API Revenue (2020-2031) & (US$ Million)

Figure 56. Asia-Pacific Lenalidomide API Sales YoY (2020-2031) & (Ton)

Figure 57. Asia-Pacific Lenalidomide API Revenue YoY (2020-2031) & (US$ Million)

Figure 58. Asia-Pacific Top 8 Manufacturers Lenalidomide API Sales Revenue (US$ Million) in 2024

Figure 59. Asia-Pacific Lenalidomide API Sales Volume (Ton) by Type (2020- 2031)

Figure 60. Asia-Pacific Lenalidomide API Sales Revenue (US$ Million) by Type (2020- 2031)

Figure 61. Asia-Pacific Lenalidomide API Sales Volume (Ton) by Application (2020-2031)

Figure 62. Asia-Pacific Lenalidomide API Sales Revenue (US$ Million) by Application (2020-2031)

Figure 63. Indonesia Lenalidomide API Revenue (2020-2031) & (US$ Million)

Figure 64. Japan Lenalidomide API Revenue (2020-2031) & (US$ Million)

Figure 65. South Korea Lenalidomide API Revenue (2020-2031) & (US$ Million)

Figure 66. China Taiwan Lenalidomide API Revenue (2020-2031) & (US$ Million)

Figure 67. India Lenalidomide API Revenue (2020-2031) & (US$ Million)

Figure 68. Central and South America Lenalidomide API Sales YoY (2020-2031) & (Ton)

Figure 69. Central and South America Lenalidomide API Revenue YoY (2020-2031) & (US$ Million)

Figure 70. Central and South America Top 5 Manufacturers Lenalidomide API Sales Revenue (US$ Million) in 2024

Figure 71. Central and South America Lenalidomide API Sales Volume (Ton) by Type (2021-2031)

Figure 72. Central and South America Lenalidomide API Sales Revenue (US$ Million) by Type (2020-2031)

Figure 73. Central and South America Lenalidomide API Sales Volume (Ton) by Application (2020-2031)

Figure 74. Central and South America Lenalidomide API Sales Revenue (US$ Million) by Application (2020-2031)

Figure 75. Brazil Lenalidomide API Revenue (2020-2025) & (US$ Million)

Figure 76. Argentina Lenalidomide API Revenue (2020-2025) & (US$ Million)

Figure 77. Middle East, and Africa Lenalidomide API Sales YoY (2020-2031) & (Ton)

Figure 78. Middle East and Africa Lenalidomide API Revenue YoY (2020-2031) & (US$ Million)

Figure 79. Middle East and Africa Top 5 Manufacturers Lenalidomide API Sales Revenue (US$ Million) in 2024

Figure 80. Middle East and Africa Lenalidomide API Sales Volume (Ton) by Type (2021-2031)

Figure 81. South America Lenalidomide API Sales Revenue (US$ Million) by Type (2020-2031)

Figure 82. Middle East and Africa Lenalidomide API Sales Volume (Ton) by Application (2020-2031)

Figure 83. Middle East and Africa Lenalidomide API Sales Revenue (US$ Million) by Application (2020-2031)

Figure 84. GCC Countries Lenalidomide API Revenue (2020-2025) & (US$ Million)

Figure 85. Turkey Lenalidomide API Revenue (2020-2025) & (US$ Million)

Figure 86. Egypt Lenalidomide API Revenue (2020-2025) & (US$ Million)

Figure 87. South Africa Lenalidomide API Revenue (2020-2025) & (US$ Million)

Figure 88. Lenalidomide API Industry Chain Mapping

Figure 89. Regional Lenalidomide API Manufacturing Base Distribution (%)

Figure 90. Lenalidomide API Production Process

Figure 91. Regional Lenalidomide API Production Cost Structure

Figure 92. Channels of Distribution (Direct Vs Distribution)

Figure 93. Bottom-up and Top-down Approaches for This Report

Figure 94. Data Triangulation

Figure 95. Key Executives Interviewed

KEY QUESTIONS ADDRESSED BY THE REPORT

Which companies rank high in the global Lenalidomide API market? zhanKai

The top companies in the global Lenalidomide API market are Dr. Reddy’s Laboratories Ltd.、Johnson Matthey PLC、Changzhou Pharmaceutical Factory.

Related Reports

Lenalidomide API- Global Market Share and Ranking, Overall Sales and Demand Forecast 2026-2032
The global market for Lenalidomide API was estimated to be worth US$ million in 2025 and is projected to reach US$ million, growing at a CAGR of %from 2026 to 2032.
Published Date: 2026-07-14
Pages: 126
USD 3950.00
(Single User License)
Global Lenalidomide API Market Research Report 2026
The global Lenalidomide API market was valued at US$ million in 2025 and is anticipated to reach US$ million by 2032, at a CAGR of %from 2026 to 2032.
Published Date: 2026-04-21
Pages: 134
USD 2900.00
(Single User License)
Lenalidomide API- Global Market Share and Ranking, Overall Sales and Demand Forecast 2025-2031
The global market for Lenalidomide API was estimated to be worth US$ million in 2024 and is forecast to a readjusted size of US$ million by 2031 with a CAGR of %during the forecast period 2025-2031.
Published Date: 2025-02-15
Pages: 99
USD 3950.00
(Single User License)
Global Lenalidomide API Market Research Report 2025
The global market for Lenalidomide API was valued at US$ million in the year 2024 and is projected to reach a revised size of US$ million by 2031, growing at a CAGR of %during the forecast period.
Published Date: 2025-02-15
Pages: 95
USD 2900.00
(Single User License)
Global Lenalidomide API Sales Market Report, Competitive Analysis and Regional Opportunities 2025-2031
The global Lenalidomide API market size was US$ million in 2024 and is forecast to a readjusted size of US$ million by 2031 with a CAGR of %during the forecast period 2025-2031.
Published Date: 2025-02-15
Pages: 77
USD 4250.00
(Single User License)
Global Lenalidomide API Market Insights, Forecast to 2030
Thalidomide and its analogue lenalidomide are immunomodulatory and antineoplastic agents that are used in the therapy of multiple myeloma. Both agents are associated with a low rate of serum aminotransferase elevations during therapy and both have been implicated in causing rare instances of clinically apparent liver injury which can be severe.
Published Date: 2024-04-15
Pages: 95
USD 4900.00
(Single User License)
Lenalidomide API - Global Market Share and Ranking, Overall Sales and Demand Forecast 2024-2030
Thalidomide and its analogue lenalidomide are immunomodulatory and antineoplastic agents that are used in the therapy of multiple myeloma. Both agents are associated with a low rate of serum aminotransferase elevations during therapy and both have been implicated in causing rare instances of clinically apparent liver injury which can be severe.
Published Date: 2024-02-23
Pages: 97
USD 3950.00
(Single User License)
Global Lenalidomide API Market Research Report 2024
Thalidomide and its analogue lenalidomide are immunomodulatory and antineoplastic agents that are used in the therapy of multiple myeloma. Both agents are associated with a low rate of serum aminotransferase elevations during therapy and both have been implicated in causing rare instances of clinically apparent liver injury which can be severe.
Published Date: 2024-01-10
Pages: 85
USD 2900.00
(Single User License)

Lenalidomide API- Global Market Share and Ranking, Overall Sales and Demand Forecast 2026-2032
The global market for Lenalidomide API was estimated to be worth US$ million in 2025 and is projected to reach US$ million, growing at a CAGR of %from 2026 to 2032.
Published: 2026-07-14
Pages: 126
USD 3950.00 (Single User License)
Global Lenalidomide API Market Research Report 2026
The global Lenalidomide API market was valued at US$ million in 2025 and is anticipated to reach US$ million by 2032, at a CAGR of %from 2026 to 2032.
Published: 2026-04-21
Pages: 134
USD 2900.00 (Single User License)
Lenalidomide API- Global Market Share and Ranking, Overall Sales and Demand Forecast 2025-2031
The global market for Lenalidomide API was estimated to be worth US$ million in 2024 and is forecast to a readjusted size of US$ million by 2031 with a CAGR of %during the forecast period 2025-2031.
Published: 2025-02-15
Pages: 99
USD 3950.00 (Single User License)
Global Lenalidomide API Market Research Report 2025
The global market for Lenalidomide API was valued at US$ million in the year 2024 and is projected to reach a revised size of US$ million by 2031, growing at a CAGR of %during the forecast period.
Published: 2025-02-15
Pages: 95
USD 2900.00 (Single User License)
Global Lenalidomide API Sales Market Report, Competitive Analysis and Regional Opportunities 2025-2031
The global Lenalidomide API market size was US$ million in 2024 and is forecast to a readjusted size of US$ million by 2031 with a CAGR of %during the forecast period 2025-2031.
Published: 2025-02-15
Pages: 77
USD 4250.00 (Single User License)
Global Lenalidomide API Market Insights, Forecast to 2030
Thalidomide and its analogue lenalidomide are immunomodulatory and antineoplastic agents that are used in the therapy of multiple myeloma. Both agents are associated with a low rate of serum aminotransferase elevations during therapy and both have been implicated in causing rare instances of clinically apparent liver injury which can be severe.
Published: 2024-04-15
Pages: 95
USD 4900.00 (Single User License)
Lenalidomide API - Global Market Share and Ranking, Overall Sales and Demand Forecast 2024-2030
Thalidomide and its analogue lenalidomide are immunomodulatory and antineoplastic agents that are used in the therapy of multiple myeloma. Both agents are associated with a low rate of serum aminotransferase elevations during therapy and both have been implicated in causing rare instances of clinically apparent liver injury which can be severe.
Published: 2024-02-23
Pages: 97
USD 3950.00 (Single User License)
Global Lenalidomide API Market Research Report 2024
Thalidomide and its analogue lenalidomide are immunomodulatory and antineoplastic agents that are used in the therapy of multiple myeloma. Both agents are associated with a low rate of serum aminotransferase elevations during therapy and both have been implicated in causing rare instances of clinically apparent liver injury which can be severe.
Published: 2024-01-10
Pages: 85
USD 2900.00 (Single User License)